Microdosing tirzepatide: How this dual-action medication is used

Introduction: A dual-action GLP-1 medication

Tirzepatide is a newer medication in the GLP-1 category. What sets it apart is that it acts on two receptors rather than one. Luvo's Microdosing Tirzepatide Program uses a lower-dose, clinician-guided approach and offers it as an injection.

This is an educational overview. It isn't medical advice or a promise of a specific result.

The dual mechanism

Tirzepatide is a dual GIP/GLP-1 receptor agonist. GLP-1 receptor activation reduces appetite, slows gastric emptying, and supports insulin signaling. GIP (glucose-dependent insulinotropic polypeptide) activation adds effects on metabolism and insulin signaling. Acting on both pathways is what distinguishes tirzepatide from single-receptor medications. Describing this mechanism is education, not a claim about results.

The microdosing approach

As with other GLP-1 medications, standard tirzepatide protocols titrate toward a maximum dose. A microdosing approach works with a lower dose and adjusts based on individual response, under provider supervision, rather than following a fixed schedule to the top of the range. Whether a lower dose is appropriate is a clinical decision.

Formulation and safety

Luvo offers Microdosing Tirzepatide as an injection, given weekly under the skin. Tirzepatide is a prescription medication with important contraindications: it isn't appropriate for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a provider screens for these and other factors. Luvo's compounded tirzepatide is not FDA-approved, and a licensed provider reviews your health history before prescribing.

Getting started

Explore Luvo's Microdosing Tirzepatide injection options, or visit the Microdosing Program.